Clinical trial registry record

Maximum Treatment Interval With Aflibercept T&E

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 25, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05342857
Last registry update
April 25, 2022
Status
Unknown
Phase
Phase not reported
Sponsor
Shin Kong Wu Ho-Su Memorial Hospital
Enrollment
100
Countries
Taiwan
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
100
Population
ALL
Duration
2022-01-01 to 2025-04-01
Intervention
Aflibercept Injection [Eylea]
Comparator
Not reported
Outcomes measured
The percentage of patients whose maximum treatment interval is extended to 24 months — 2 years; Find the prediction factors associated with extension to 16 weeks and beyond by univariate and multivariate analysis —…; Find the prediction factors associated with occurrence of disease activity by univariate and multivariate analysis — 2…; The percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months in PCV and…; Mean change in BCVA from baseline to month 24 — 2 years; Mean change in central subfield thickness from baseline to month 24 — 2 years; Proportion of patients who gain ≧15 ETDRS letters from baseline to month 24 — 2 years; Mean number of injections in each group from baseline to month 24 — 2 years; Mean treatment interval from baseline to month 24 — 2 years
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON